Format

Send to

Choose Destination
Clin Appl Thromb Hemost. 2017 Nov;23(8):928-937. doi: 10.1177/1076029616663849. Epub 2016 Aug 29.

Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia: Meta-Analysis of Randomized Controlled Trials.

Author information

1
1 Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
2
2 Medical Research Group of Egypt, Cairo, Egypt.
3
3 Kasr Al Ainy School of Medicine, Cairo University, Egypt.
4
4 Faculty of Medicine, Alexandria University, Alexandria, Egypt.

Abstract

BACKGROUND:

Eltrombopag is an oral thrombopoietin receptor agonist that stimulates the production of normally functioning platelets. The aim of this meta-analysis is to synthesize evidence about the safety and efficacy of eltrombopag for both adult and children with primary immune thrombocytopenia (ITP).

METHODS:

A computer literature search of PubMed, Scopus, Web of Science, and Cochrane Central was conducted. Records were screened for eligible studies, and data were extracted and synthesized using Review Manager for Windows. Subgroup analysis and sensitivity analysis were conducted to investigate whether treatment effect varies significantly between adults and children.

RESULTS:

Six randomized controlled trials (N = 611 patients) were included in the final analysis. The overall effect estimates favored eltrombopag group in terms of overall platelet response (relative risk [RR]: 3.42; 95% confidence interval [CI]: 2.51-4.65; P < .0001), incidence of significant bleeding (RR: 0.56; 95% CI: 0.41-0.77; P = .0004), and number of cases needed to rescue treatment (RR: 0.45; 95% CI: 0.32-0.65; P < .0001). The efficacy of eltrombopag did not differ significantly between children and adults except for incidence of any bleeding (RR: 0.83 vs 0.51; P = .008).

CONCLUSION:

Eltrombopag is a tolerable and effective drug for the management of chronic ITP in children and adults.

KEYWORDS:

efficacy; eltrombopag; immune thrombocytopenia; thrombopoietin agonists

PMID:
27572890
DOI:
10.1177/1076029616663849
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center